Europe Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)
The Europe infectious disease therapeutics market was valued at US$ 35,451.86 million in 2022 and is expected to reach US$ 49,108.21 million by 2030; it is estimated to register a CAGR of 4.2% from... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe Europe infectious disease therapeutics market was valued at US$ 35,451.86 million in 2022 and is expected to reach US$ 49,108.21 million by 2030; it is estimated to register a CAGR of 4.2% from 2022 to 2030.Increasing Focus on Funding and R&D in Infectious Disease Therapeutics Drives Europe Infectious Disease Therapeutics Market Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share. In order to create solutions for the most important health issues that Europe and the rest of the world are currently encountering, the European Union is investing in research, technology, and innovation. The European Commission has led the way in promoting research, particularly that related to immunity to and management of infectious diseases. Between 2007 and 2019, more than US$ 4.3 billion (4 billion) was allocated to the study of infectious diseases. Further, Horizon Europe, the upcoming (2021-2027) EU funding initiative for research and innovation (R&I), will carry on supporting R&I for infectious diseases, notably those associated with poverty, those that are neglected, and those that are (re-)emerging. Horizon Europe is a program dedicated to supporting research and innovation. To bridge barriers across regions and establish tangible collaborations, the program places a strong emphasis on ensuring cooperation between universities, scientific communities, industry, especially small and medium-sized firms, and individuals. The Health Work Programme outlines funding options under Horizon Europe for research related to infectious diseases and pandemic preparedness and response. Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth. Europe Infectious Disease Therapeutics Market Overview The Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global infectious disease therapeutics market and is estimated to register a notable CAGR during 2022-2030. The region has an increased incidence of chronic viral diseases and a high demand for developing new anti-viral drugs. With US$ 15.79 billion funded from 2007 to 2019 through the 7th Framework Program and Horizon 2020 and the US$ 1.1 billion pledged for COVID-19 research, Europe plays a crucial role in funding and coordinating research on infectious diseases. According to The Robert Koch Institute, in Germany, ~400,000 to 600,000 patients suffer a hospital-acquired infection each year, among which 10,000-15,000 die. Typical problems for healthcare providers are surgical site infections, urinary tract infections, and pneumonia. The demand for anti-infective agents in Germany is growing significantly, attributed to the rising geriatric population, the increasing prevalence of chronic viral diseases, and the growing demand to produce new molecules for viral therapeutic areas to fulfill unmet conditions. Germany is one of the leading nations for anti-viral agent manufacturing and growth potential in Europe due to the high quality of its finished products. For instance, Atriva Therapeutics GmbH, a biopharmaceutical company, developed ATR-002 to treat patients with COVID-19 in a Phase II Study to block viral propagation of SARS-CoV-2. Therefore, due to the abovementioned factors, the market is expected to grow significantly in the country. Europe Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million) Europe Infectious Disease Therapeutics Market Segmentation The Europe infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country. Based on drug class, the Europe infectious disease therapeutics market is segmented into anti-viral, anti bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022. In terms of indication, the Europe infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022. Based on route of administration, the Europe infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022. In terms of distribution channel, the Europe infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022. By country, the Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe infectious disease therapeutics market share in 2022. AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Europe infectious disease therapeutics market. Table of ContentsTABLE OF CONTENTS1. Introduction 1.1 The Insight Partners Research Report Guidance 1.2 Market Segmentation 2. Executive Summary 2.1 Key Insights 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics 4.1 Europe Infectious Disease Therapeutics Market - Key Market Dynamics 4.2 Market Drivers 4.2.1 Rising Prevalence of Infectious Disease 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics 4.3 Market Restraints 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects 4.4 Market Opportunities 4.4.1 Escalating Threat of Antibiotic Resistance 4.5 Future Trends 4.5.1 Rising Number of Product Approvals and Launches 4.6 Impact of Drivers and Restraints: 5. Infectious Disease Therapeutics Market - Europe Analysis 5.1 Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030 6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class 6.1 Overview 6.2 Anti-Viral 6.2.1 Overview 6.2.2 Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.3 Anti-bacterial 6.3.1 Overview 6.3.2 Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.4 Anti-fungal 6.4.1 Overview 6.4.2 Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 6.5 Others 6.5.1 Overview 6.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7. Europe Infectious Disease Therapeutics Market Analysis - by Indication 7.1 Overview 7.2 HIV 7.2.1 Overview 7.2.2 HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.3 Hepatitis 7.3.1 Overview 7.3.2 Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.4 Tuberculosis 7.4.1 Overview 7.4.2 Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.5 Influenza 7.5.1 Overview 7.5.2 Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.6 HPV 7.6.1 Overview 7.6.2 HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 7.7 Others 7.7.1 Overview 7.7.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration 8.1 Overview 8.2 Oral 8.2.1 Overview 8.2.2 Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.3 Parenteral 8.3.1 Overview 8.3.2 Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.4 Topical 8.4.1 Overview 8.4.2 Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 8.5 Others 8.5.1 Overview 8.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel 9.1 Overview 9.2 Hospital Pharmacies 9.2.1 Overview 9.2.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9.3 Retail Pharmacies 9.3.1 Overview 9.3.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 9.4 Others 9.4.1 Overview 9.4.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10. Europe Infectious Disease Therapeutics Market - Country Analysis 10.1 Europe Infectious Disease Therapeutics Market 10.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country 10.1.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country 10.1.1.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.2.1 Overview 10.1.1.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.4.1 Overview 10.1.1.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.6.1 Overview 10.1.1.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.8.1 Overview 10.1.1.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration 10.1.1.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.10.1 Overview 10.1.1.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 10.1.1.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.12.1 Overview 10.1.1.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) 10.1.1.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class 10.1.1.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication 10.1.1.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration 10.1.1.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel 11. Infectious Disease Therapeutics Market-Industry Landscape 11.1 Overview 11.2 Growth Strategies in the Infectious Disease Therapeutics Market 11.3 Inorganic Growth Strategies 11.3.1 Overview 11.4 Organic Growth Strategies 11.4.1 Overview 12. Company Profiles 12.1 Pfizer Inc 12.1.1 Key Facts 12.1.2 Business Description 12.1.3 Products and Services 12.1.4 Financial Overview 12.1.5 SWOT Analysis 12.1.6 Key Developments 12.2 Gilead Sciences Inc 12.2.1 Key Facts 12.2.2 Business Description 12.2.3 Products and Services 12.2.4 Financial Overview 12.2.5 SWOT Analysis 12.2.6 Key Developments 12.3 F. Hoffmann-La Roche Ltd 12.3.1 Key Facts 12.3.2 Business Description 12.3.3 Products and Services 12.3.4 Financial Overview 12.3.5 SWOT Analysis 12.3.6 Key Developments 12.4 Shionogi & Co Ltd 12.4.1 Key Facts 12.4.2 Business Description 12.4.3 Products and Services 12.4.4 Financial Overview 12.4.5 SWOT Analysis 12.4.6 Key Developments 12.5 Bayer AG 12.5.1 Key Facts 12.5.2 Business Description 12.5.3 Products and Services 12.5.4 Financial Overview 12.5.5 SWOT Analysis 12.5.6 Key Developments 12.6 BioCryst Pharmaceuticals Inc 12.6.1 Key Facts 12.6.2 Business Description 12.6.3 Products and Services 12.6.4 Financial Overview 12.6.5 SWOT Analysis 12.6.6 Key Developments 12.7 GSK Plc 12.7.1 Key Facts 12.7.2 Business Description 12.7.3 Products and Services 12.7.4 Financial Overview 12.7.5 SWOT Analysis 12.7.6 Key Developments 12.8 AbbVie Inc 12.8.1 Key Facts 12.8.2 Business Description 12.8.3 Products and Services 12.8.4 Financial Overview 12.8.5 SWOT Analysis 12.8.6 Key Developments 12.9 Merck & Co Inc 12.9.1 Key Facts 12.9.2 Business Description 12.9.3 Products and Services 12.9.4 Financial Overview 12.9.5 SWOT Analysis 12.9.6 Key Developments 12.10 Astellas Pharma Inc 12.10.1 Key Facts 12.10.2 Business Description 12.10.3 Products and Services 12.10.4 Financial Overview 12.10.5 SWOT Analysis 12.10.6 Key Developments 13. Appendix 13.1 About The Insight Partners
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(通信回線)の最新刊レポート
The Insight Partners 社の最新刊レポート
本レポートと同じKEY WORD(administration)の最新刊レポート
よくあるご質問The Insight Partners社はどのような調査会社ですか?The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/08 10:26 148.90 円 163.91 円 197.75 円 |